

Adult CIRB - Late Phase Emphasis Meeting Agenda

March 4, 2021

I Continuing Review

A021502, Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer) (Protocol Version Date 10/29/20)

II Continuing Review

A071601, Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas (Protocol Version Date 09/22/20)

III Continuing Review

E1910, A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults (Protocol Version Date 12/03/19)

IV Continuing Review

EA8153, Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHARTED2 Trial (Protocol Version Date 05/30/19)

V Continuing Review

NRG-GY016, A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epcadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary (Protocol Version Date 06/11/20)

VI Continuing Review

NRG-HN006, Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer (Protocol Version Date 06/10/20)

VII Continuing Review

S0777, A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (Protocol Version Date 09/03/19)

VIII Continuing Review

S0819, A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) (Protocol Version Date 10/03/16)

IX Continuing Review

S1512, A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM) (Protocol Version Date 02/19/20)

X Continuing Review

S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer (Protocol Version Date 07/22/19)

XI New Study - Initial Review

A051902, A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas (Protocol Version Date 01/20/21)

C>I>R>B

FOR THE NATIONAL CANCER INSTITUTE
